Research image darker c2.jpg

Accelerating the development of advanced diagnostic tools and effective treatments for systemic amyloidosis through collaboration and innovation


Transform the Research Landscape


The Amyloidosis Research Consortium has been established to address critical needs in clinical trials and related research for the underserved group of systemic amyloid diseases. 

ARC is addressing the urgent, unmet medical needs in amyloidosis.


Take Action; Participate in Our Survey


If you or a loved one has  ever had a diagnosis of amyloidosis with heart involvement, please take a few moments to fill out this important survey. Martha Grogan, MD, a cardiologist at the Mayo Clinic and the Amyloidosis Research Consortium designed this survey in order to study the barriers that patients experience with pursuing a diagnosis.   The results will be shared at the annual American Cardiology Conference in March and used to educate, engage and inform medical professionals about ways to diagnose patients earlier. You can play an important role in helping us educate physicians.

Please spare a few minutes to help us raise awareness of amyloidosis.



Rare, Underserved and Underdiagnosed


Amyloidosis is a disorder caused by proteins that possess abnormal conformational features leading them to aggregate and infiltrate tissues in the form of amyloid fibrils. Systemic amyloidosis is a disease that can damage the heart, kidneys, liver, soft tissue and nervous system, resulting in multi-organ failure and death. 

Awareness and understanding of these diseases is the first step to delivering better outcomes for patients.


Deliver Actionable Solutions for Patients


As a patient led organization ARC has firsthand knowledge of how amyloidosis affects our community. We engage scientists, policymakers and government regulators as partners in our efforts to breakdown barriers to research and drug development. 

Scientific progress is maximized when supported by sound public policy and advocacy.


Optimize, Collaborate and Share


Our Collaborative Network speeds the delivery of new and better therapies to patients with amyloidosis.  This network consists of a highly collaborative team of core amyloidosis centers, devoted to all the types of systemic amyloidosis. 

Find out more about our Clinical Trials Network and Core Member Centers.